Development

Articles

Roche will gain full rights to Inflazome’s portfolio which includes clinical and preclinical orally available small molecule NLRP3 inhibitors.

Roche Closes Agreement with Inflazome for $450 Million

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Risk-based decision-making is impacting all aspects of manufacturing quality from raw material supply to facility inspections. 

Tracking API Quality During a Pandemic

Jennifer Markarian is manufacturing editor of BioPharm International.

For certain APIs, including semi-synthetic antibiotics, continuous filtration and drying improves productivity and quality.

Considering Continuous Filtration and Drying

CARBOGEN AMCIS has announced significant investments to increase manufacturing capacity in Switzerland and France.

CARBOGEN AMCIS Invests Heavily in Switzerland and France

Atomwise’s technology, AtomNet, works to eliminate the barriers of physical screening for small molecule drug discovery.

Colorcon Ventures Invests in AI Solutions Provider

CordenPharma added a 3000-L solid-phase peptide synthesis vessel to its GMP API facility in Boulder, CO.

CordenPharma Increases US Peptide Manufacturing Capacity

HHS announces $354 million in funding for private industry to manufacture generic drugs in the US from raw materials to finished product.

BARDA Funds US-based Drug Manufacturing Initiative

Quartic.ai and Bright Path Laboratories have agreed to develop an artificial intelligence (AI)-powered continuous manufacturing platform for APIs and other small-molecule drugs using Bright Path Labs’ continuous bioreactor and the Quartic.ai smart manufacturing technology.

Quartic.ai and Bright Path Labs Will Use AI for API Continuous Manufacturing

Many antibody-drug conjugate therapies are in the pipeline; however, only a handful have been approved. What are the bottlenecks? 

Formulating an ADC Development Solution

Agnes Shanley is senior editor of Pharmaceutical Technology.

Discovery of carcinogenic nitrosamines in three of the world’s most widely prescribed drugs is driving efforts to better detect, control and prevent their generation in APIs and finished drug products.


API Synthesis and Manufacturing, Small Molecule